<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794529</url>
  </required_header>
  <id_info>
    <org_study_id>METCZ20220060</org_study_id>
    <nct_id>NCT05794529</nct_id>
  </id_info>
  <brief_title>Lung Tumor Protein Synthesis Rates in Lung Cancer Patients</brief_title>
  <acronym>LungMaas</acronym>
  <official_title>Characterizing Tissue Protein Synthesis Rates of Non-small Cell Lung Carcinomas in Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will recruit lung cancer patients to measure tissue protein synthesis rates&#xD;
      of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of&#xD;
      healthy lung tissue will be compared to lung tumor tissue to establish the remodeling&#xD;
      characteristics of healthy versus cancerous lung tissues. We will also examine whether tissue&#xD;
      protein synthesis rates of non-small cell lung carcinomas are associated with various tumor-&#xD;
      (i.e., size, subclassification) and patient-derived (i.e., inflammation, lung function,&#xD;
      smoking status, and smoking history) parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung tumor fractional synthetic rate</measure>
    <time_frame>5 days prior to surgery</time_frame>
    <description>units: % per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung tissue fractional synthetic rate</measure>
    <time_frame>5 days prior to surgery</time_frame>
    <description>units: % per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle tissue fractional synthetic rate</measure>
    <time_frame>5 days prior to surgery</time_frame>
    <description>units: % per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GH concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: mU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IGF-1 concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IGFBP-1 concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: ug/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IGFBP-3 concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: ug/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma CRP concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IL-1 concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: ng/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IL-6 concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: ng/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IL-10 concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: ng/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma TNF-alpha concentrations</measure>
    <time_frame>Baseline</time_frame>
    <description>units: ng/L</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lung cancer patient</arm_group_label>
    <description>Lung cancer patients diagnosed a non-small cell lung carcinoma requiring resection surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There are no interventions in the present study</intervention_name>
    <description>There are no interventions in the present study</description>
    <arm_group_label>Lung cancer patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In total, we will recruit 30 lung cancer patients (diagnosed with a NSCLC) scheduled to&#xD;
        undergo surgery. The nature and the risks of the experimental procedures will be explained&#xD;
        to all subjects before their informed consent will be obtained. All subjects will be&#xD;
        recruited through contact with their Surgeon at the Department of surgery at Zuyderland&#xD;
        Medical Centre, Heerlen.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-65 years&#xD;
&#xD;
          2. Compos mentis&#xD;
&#xD;
          3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neoadjuvant chemo- or radiotherapy in the past four weeks&#xD;
&#xD;
          2. Use of systemic steroids in the past four week&#xD;
&#xD;
          3. Insulin-dependent diabetes mellitus&#xD;
&#xD;
          4. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Holwerda, PhD</last_name>
    <phone>+31433881381</phone>
    <email>andy.holwerda@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zuyderland Medical Center</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik de Loos, MD</last_name>
      <email>e.deloos@zuyderland.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 15, 2023</study_first_submitted>
  <study_first_submitted_qc>March 31, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 31, 2023</last_update_submitted>
  <last_update_submitted_qc>March 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is currently no plan to share data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

